MUDr. Miroslav Koliba s.r.o. — Clinical Trial Site

9 Registered trials

6 Currently recruiting

Organisation

MUDr. Miroslav Koliba s.r.o.

Location

Ostrava, Czechia

Identifier

ORG-100050197

Address

Kubalova 388/47, Vyskovice, 700 30, Czechia

Departments

diabetology
Diabetology and pediatric clinic
N/A
NA

Clinical trials at this site (9)

Search interface

OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
A Phase 3, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil and Contezolid Compared … Recruiting

2022-500257-16-00 Diabetic Foot Infections 5 2023-03-17
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney D… Recruiting

2025-523123-22-00 Chronic Kidney Disease 5 2026-05-07
A Study of Eloralintide (LY3841136) in Participants with Obesity or Overweight, and Type 2 Diabetes (ENLIGHTEN-2) Recruiting

2025-523658-15-00 Obesity 5 2026-04-10
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting

2023-508162-15-00 Chronic HF and comorbid impairment of kidney function w 5 2024-07-12
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended

2023-508630-34-00 Overweight 5 2024-05-28
A Study of Daily Oral Orforglipron Compared with Insulin Glargine in Participants with Type 2 Diabetes and Obesity or Overweight at Increase… Ended

2022-502833-25-00 Obesity 5 2023-08-02